Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Ross Moat Sells 75,608 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Ross Moat sold 75,608 shares of the company’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $93.13, for a total transaction of $7,041,373.04. Following the completion of the transaction, the chief operating officer owned 10,294 shares in the company, valued at approximately $958,680.22. This trade represents a 88.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ross Moat also recently made the following trade(s):

• On Monday, November 2nd, Ross Moat sold 27,977 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $92.36, for a total transaction of $2,583,955.72.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $93.29 on Wednesday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $98.48. The firm has a market cap of $7.28 billion, a PE ratio of 71.76 and a beta of 0.07. The company has a 50 day simple moving average of $79.67 and a two-hundred day simple moving average of $60.56.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The business had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. As a group, research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Citigroup upped their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Wedbush lifted their price target on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. JPMorgan Chase & Co. upped their price objective on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Finally, The Goldman Sachs Group increased their price objective on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Ethic Inc. bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $726,000. Pictet Asset Management Holding SA grew its holdings in shares of Kiniksa Pharmaceuticals International by 41.3% during the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after purchasing an additional 251,578 shares during the last quarter. AlphaCentric Advisors LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at $596,000. Commonwealth Equity Services LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock valued at $811,000 after purchasing an additional 237 shares during the last quarter. Finally, Chicago Partners Investment Group LLC purchased a new position in Kiniksa Pharmaceuticals International in the 3rd quarter worth $226,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

More Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.